Background
Bladder cancer (BC) represents a global problem for the urinary tract, statistically situated in fifth place in terms of mortality and morbidity [
1]. BC incidence is higher in aged populations and is correlated with toxic environmental agents, in particular with smoking [
2]. The prognosis of BC is unfavorable, with a high percentage of disease recurrence regardless of treatment; these treatments include surgery, chemotherapy or, a combination of these two [
1]. About 70–75% of BC cases are defined as non-muscle invasive tumors, subclassified into low or high-grade tumors [
3‐
5]. The identification of high-risk tumors is imperative and requires intravesical therapy as a standard practice [
6].
BC is a multifactorial disease where both exogenous and endogenous factors are eessential in early carcinogenesis, disease progression but also responsible for the high recurrence rate, correlating to a specific mutation pattern [
7]. Therefore, new biomarkers for early diagnosis of bladder cancer, prognostic markers for its recurrence and predictive markers for response/overall survival are needed with great urgency [
8]. Molecular markers can provide vital information to refine the optimal treatment, which in turn permits a good patient prognosis [
5].
MicroRNAs (miRNAs) are a novel class of short non-coding RNA sequences that have around 19–25 nucleotide length [
8,
9]. These short non-coding structures can regulate gene expression and interfere with vital cellular pathways without being translated into proteins, including in cancer biology. A miRNA can target multiple genes, several miRNAs can target a gene and this gives rise to complex interaction networks; presently, the exact interactions have yet to be determined especially in relationship to the mutational status [
8,
10]. Accordingly, miRNAs are essential candidates for both diagnosis and prognosis due to their oncogenic or tumor suppressor functions. Hence, miRNAs profiling studies from different tissues represent an excellent alternative application for these short sequences as biomarkers with clinical significance [
11]. The main advantage is the high stability of these transcripts, remaining unaltered during the surgical resection procedure (TURB), which is often associated with a high degradation rate [
12,
13]. Another advantage is the full range of tools and methods for miRNAs profiling (microarray, next-generation sequencing or Nanostring) or validation (qRT-PCR or in situ hybridization) [
8].
Previous studies have examined miRNAs in BC; however, very few cases examine the global miRNA expression patterns by microarray in paired samples with subsequent overlapping using TCGA miRNA data. We utilized this combined data set to identify specific pathways associated with BC. Following the profiling of bladder cancer samples, we used Ion Torrent Next Generation Sequencing Cancer panel to determine the most relevant mutations in our patient cohort and TCGA dataset. The correlation of this data permits a better understanding of the interconnected regulatory networks that appear to have significant biological meaning in terms of tumor molecular phenotype and gene expression profiles; all this to be exploited as candidates for future therapies or as prognostic/diagnostic biomarkers.
Material and methods
Sample collection
Between 2014 and 2016, we collected the tumoral BC tissue along with the adjacent healthy tissue from patients, only after obtaining informed consent from each patient and approval by the institutional ethics committee of the Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania (UMPh), with the authorization no. 673A/20.11.2012. We stored transurethral resections of bladder tumor (TURBT) tissues in liquid nitrogen until sample processing and RNA extraction. When surgical and pathological procedures permitted, surgeons collected the healthy tissue, adjacent from the tumor, from each patient. We initially evaluated the expression of Her2 and TP53 using the standard immunohistochemistry staining protocol. The paired (healthy and tumor) tissue samples later used for the microarray and next-generation sequencing analyses are referred to as UMPh patient cohort. The second group of samples collected was for the qRT-PCR validation and named the validation set; we collected this additional patient cohort.
Sample processing and microarray evaluation
The total RNA extraction and isolation from 23 paired samples (normal and tumoral bladder tissue) is done using the TriReagent (Sigma-Aldrich) protocol. NanoDrop-1000 spectrophotometer was used to measure the concentration of RNA. The microarray probes were synthesized from equal quantities of 100 ng of total RNA, by using miRNA microarray protocol based on version 3.1 of September 2015 (Agilent Technologies) which included complete labeling and hybridization kit (cat no. 5190–0456 Agilent) and a purification step with Micro Bio-Spin P-6 Gel Column (Biorad). The SureScan Microarray Scanner (Agilent Technologies) scanned the microarray slides and Feature Extraction 12.0 software performed data extraction. The last step in the microarray evaluation was to identify the primary altered miRNAs. Gene Spring GX v.13.0, applying a fold change (FC) threshold of 2 moderated t-test and False Discovery Rate correction (p-valued ≤0.05), analyzed the microarray data and generated the comparisons of low-grade versus high-grade tumor tissues; low-grade tumor versus healthy tissues; high-grade tumors versus healthy tissues (data available on Arrayexpress, ID: E-MTAB-8356).
Bladder cancer TCGA data analysis
We performed a supplementary analysis at the third level of miRNAs-sequencing from 409 bladder tumors and 19 healthy tissues, adjacent to the tumors, obtained from the TCGA data portal (
https://tcga-data.nci.nih.gov/tcga/). The data were analyzed in GeneSpring GX v.13.0, applying the previous defined cut-off value.
miRNA qRT-PCR evaluation on tissue samples
We selected to validate three upregulated transcripts (miR-23a, miR-141-3p and miR-205-5p) and two downregulated transcripts (miR-139-5p, and miR-143-5p) from the paired tissue samples. RNA was extracted using TriReagent based method for qRT-PCR validation was performed on 18 healthy bladder tissues and 18 bladder tumor tissues. We performed the cDNA synthesis using a 7.5 μl of reverse transcription mixture containing 0.72 μl of RT primer, 50 ng of total RNA and 0.5 μl of MultiScribe Reverse Transcriptase, 0.75 μl Reverse Transcription Buffer (10×), 0.075 μl dNTPs (100 mM), 0.1 μl of RNase Inhibitor according to Taqman MicroRNA Reverse Transcription Kit (Applied Biosystems) protocol. The cDNA mixture is incubated in PCR tubes for 30 min at 16 °C, 30 min at 42 °C and 5 min at 85 °C. qRT-PCR was performed using the in ViiA7 (Applied Biosystems) PCR machine with a total volume of reaction mix of 12.5 μl; this reaction mix consists of 6.25 μl of cDNA (diluted 1:6 with nuclease-free water), 5.63 μl of SSoAdvanced Universal Probe Supermix (Bio-Rad) and 0.73 μl primers for each miRNA. The reactions were set up as follows: initial denaturation step at 95 °C for 180 s, followed by 39 cycles of 95 °C for 5 s and, lastly, 60 °C for the 30s. The expression level of each miRNA is calculated by the threshold cycle (CT). The relative expression level was calculated using –ΔΔCT method and U6 for normalization.
TP53 evaluation by qRT-PCR on bladder tissue samples
Lab technicians synthesized the cDNA using High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems). The reaction preparation of qRT-qPCR used the SYBR Select Master Mix (Life Technologies) and executed using ViiA7. The following conditions were used: 95 °C for 2 min, 40 cycles of 95 °C for 10 s and 60 °C for 1 min. The FC of gene expression was calculated with the ΔΔCT method, using B2M as the housekeeping gene.
Next-generation sequencing of bladder cancer samples
A number of 22 bladder cancer samples, the same ones analyzed by microarray (except one samples from microarray patien cohort with low DNA concentration), were sequenced using Ion Ampliseq Cancer Panel and Ion Torrent PGM Next Generation Sequencing (Thermo Fischer Scientific); this panel contains the most relevant hot spot mutation. The amplicon libraries were prepared with 20 ng of DNA and the Ion Ampliseq™ Library Kit 2.0 (Life Technologies) and this was followed by a purification step using AMpure XP Beads (Beckman Coulter). Lastly, Qubit 2.0 was used for the quantification using Qubit HS DNA kit. For sequencing, four bar-coded 100pM-diluted libraries were used for each Ion 316 Chip (Thermo Fischer Scientific). Ion Torrent PGM Machine (Thermo Fischer Scientific) performed the sequencing, using the Ion PGM HI-Q Sequencing 200 kit. The software Torrent Suit 5.6 and Ion Reporter 5.6 executed the bioinformatics analysis, specifically for data trimming alignment and variant calling.
Functional analysis and target genes identification
Discussions
Bladder cancer is a very heterogeneous disease, which makes the matched/paired samples advantageous in analyzing their molecular profile. This allows a miRNAs profiling evaluation from a limited number of patients; however, it is the overlapping with TCGA data that specifically permits the identification of the most representative altered transcripts. The importance to understanding any disease is not in the specific quantifications of certain transcriptomic information (like miRNA). Rather in how this transcriptomic information relates to specific genetic alterations and their intrinsic cellular mechanisms, which affect the equilibrium therein facilitating the progression of or toward the disease.
It was identified a specific miRNA pattern in bladder cancer, from which a selected subset of individual miRNAs and their combinations were associated with overall survival rate. This study represents the basis for developing miRNA expression signatures as diagnostic tools for BC and also encourages our comprehension of the miRNA function in the initiation or progression of disease. The integrated miRNA profiling of bladder carcinomas reported here extends our knowledge based on building a comprehensive characteristic miRNAs signature with clinical importance for prognosis or diagnosis.
Our data demonstrates consistent dysregulation of miRNAs in bladder cancer. Some of the altered miRNAs are exhibited in all the cancer types like the cases of let-7 family members [
14‐
18]. Also, miR-21 is a commonly up-regulated miRNA in human cancers, which also appears to be consistent in our case. In bladder cancer in vitro models, miR-21 is able to regulate cell proliferation and migration via its cross talk with PTEN and TP53 [
19], this is one of the most important pathways related to bladder carcinogenesis [
20]. A recent study confirmed the altered expression level for miR-21, miR-205 and miR-200c in bladder cancer when analyzing data generated by pairing the tissue to plasma samples [
21]. As the previous authors concluded, we did find miR-205 to be specific to bladder tumor tissue and, in addition, this miRNA was consistently upregulated.
In addition, we were able to identify specific miRNAs signatures for epithelial transition to mesenchymal state (EMT). EMT is a well-known process related to tumor invasion, drug resistance and potential to be stem cell-like [
22]. These EMT related transcripts particularly regulate loss of adhesion, leading to increasing cell motility which facilitates metastasis. It was demonstrated that genes
BCL2,
CDH11,
ZEB1/ZEB2 and
TIMP2 are targeted respectively by miR-200b/c, miR-200c and miR-200c causing this regulatory effect on adhesion and indirect regulation of EMT [
23‐
26], also emphasis in Fig.
3d.
There appears to be an inverse relationship between the expression of the miR-200 family, particularly miR-200c and miR-141, and the expression of E-cadherin and concurrently exhibiting significant downregulation of ZEB1 expression [
27]. This provides an important therapeutic target worth investigating further explicitly for bladder cancer to re-enforce the adhesion between cells and hinder EMT. Detailed evaluation of the expression level of the miR-200 family (miR-141/200c and miR-200a/200b/429) has shown frequent upregulation in BC, but are frequently downregulated in other cancer types, like renal cancer [
28]. MiR-200c expression level is associated with early stage T1 bladder tumor progression [
29]. More specifically, miR-200c downregulation was connected with progression to muscle invasive bladder cancer and unfavorable prognosis [
29]. Other miRNAs with an altered expression level in bladder cancer involved in EMT and invasion is miR-141. In multiple other pathologies [
30], not only bladder cancer [
31], miR-200c and miR-141 were considered prognostic markers [
32]. It should be noted that for the range of bladder cancer samples studied, the expression levels of miR-205 and miR-200c are highly disputed [
22,
33,
34], often reported as both downregulated [
35] and overexpressed [
17].
In a recent review paper, miR-145 was presented as a frequently miRNA downregulated in bladder cancer [
27,
36,
37], which was confirmed by our data. miR-143/145 is presented as clustered in the literature with tumor suppressor function in a wide range of cancers, including bladder cancer [
28,
38]. We found that miR-143 had a downregulated expression in the bladder tumor tissue and that it interacts with RAS, ERK, P53, Rb or E2F (Fig. 8). Some authors argue that the downregulated miR-143 is regulated by the oncoprotein EZH2, frequently overexpressed in bladder cancer, representing an important therapeutic target not only a biomarker [
39,
40].
Several studies present miR-133b to be downregulated in bladder cancer, but also in other cancers [
36,
41]. It not only targets the mechanism of apoptosis and cell proliferation [
42], but also migration and invasions via EGFR (epidermal growth factor receptor) and its downstream or upstream effectors [
43,
44]. Another one of our downregulated transcripts is miR-139, whose expression level, interaction with MMPs (Fig. 8) and associated gene network of focal adhesion (Additional file
7: Figure S2B) are consistent with literature data [
45,
46].
For bladder cancer, a number of the altered miRNAs were proven to regulate TP53 network at multiple levels [
28,
50], emphasizing the importance of TP53 status. TP53 overexpression (by IHC) was proven to be associated with the presence of mutation in this gene that leads to its inactivation. In turn, inactivation of TP53 promotes tumorigenesis in cancer cells and, not coincidently, is correlated to poor survival in human tumors. A study done by Puzio-Kuter et al. (2009) demonstrated that the combined inactivation of TP53 and p10 in bladder epithelium lead to an invasive cancer characteristic in mouse models [
51]. The authors claimed that the synergy of deleting both p53 and p10 is mediated by deregulation of mTOR signaling. Specifically, TP53 was observed to interact with miR-200a, miR-214, miR-513 and miR-1225. Additionally, miR-19 provides a possible link between the TP53, KDR, ERBB4 and PIK3CA. Low-grade carcinoma usually have
PIK3CA mutation and it progresses into high grade tumor after in inactivation CDKN2A [
52]. The presence of specific SNP on the level of
PIK3CA was related with bladder cancer risk. Therefore, recognizing and targeting genetic variations of the PI3K/AKT/mTOR pathway has an important clinical implication for bladder cancer prognosis [
53].
TP53 mutation alteration of the receptors tyrosine kinase pathways are observed in our investigation, which is in agreement with literature date. This pathway is activated in around 40% bladder cancer cases (
FGFR3: > 10%,
EGFR:> 10%,
ERBB2:~ 10%,
ERBB3:~ 10%,
NRAS/HRAS/KRAS:~ 10%,
PTEN: ~ 10%,
AKT3:~ 10%) [
54]. TCGA data revealed 58 significantly mutated genes and high incidence of several genetic pathways [
52]. In our study, an important difference between the overall survival of
TP53 mutant and wild-type was confirmed; a fact established by previous studies on bladder cancers [
55‐
57]. Literature data reports frequent alterations on the expression levels of FGFRs [
7,
58], which if further clarified and has significant role in the response to therapy [
59,
58]. In our case, a single exonic mutation (exonic: NM_000142.4) in 13/24(54%) was identified and determined to be pathogenic using the FATHMM web server.
FGFR3 and
TP53 have proven to have a higher incidence of mutation in our analyzed samples. Using miRnet database, we demonstrated (see Additional file
8: Figure S3.) that these genes do interact with several miRNAs that were altered in our investigation, however, the specifics of the interaction has yet to be discovered. Based on our results and using the KEGG database, in Fig. 8 we proposed interactions between the genes associated to BC carcinogenesis and our altered miRNAs expressions (▼ miR-139-5p; ▼ miR-143-5p; ▲ miR-23a-3p; ▲ miR-141-3p; ▲ miR-205-5p). In the end, it is important to highlight the complexity of the transcriptome and its interactions with the genome, especially if mutational status is added as another level of analysis.
Lastly, ERBB4 (the epidermal growth factor receptor 4) belong to the ERB family of growth factor receptor tyrosine kinases (TKI) being involved in the regulation of cell proliferation, cell differentiation, migration and invasion related in mechanism by two major pathways Ras/Raf/MAPK and PI3K/Akt/mTOR signaling [
60]. The presence of this type of mutation was identified in 11 of our 23 paired samples analyzed and has a clinically important application in predicting the response to TKI inhibitors. ERBB4 mutated gene has been shown to be interconnected with the aforementioned miR-145 and miR-193a, but we identified only an intronic mutation, with no pathogenic effect.
Conclusions
Alteration of the miRNAs expression level affects tumor molecular phenotype. These changes are detectable indirectly through the pathways with which they exhibit BC; for example, the presence of some specific mutations in key genes found in these pathways. Genes are acted upon by miRNAs where altering their expression acts on a variety of functions that impact cancer development and prognosis. More specific examples can be found with the EMT related miRNAs (miR-141b, miR-200 s or miR-205) that have an important role in the molecular mechanisms, underlying key processes related to tumorigenesis, invasion and metastasis.
To further extend the complexity of interactions, miRNAs can simultaneously target multiple components of the same signaling pathway or of multiple signaling pathways. By integrating of relevant mutations with the altered miRNA expressions, a better insight into this complex network is attained which contributes to an enhanced understanding of bladder cancer tumorigenesis, progression and recurrence. The combined understanding of molecular data facilitates the identification of important targets at cellular level that will lead to new clinical and biological strategies to manage a personalized treatment in BC [
61]. Although the numbers of cases were limited in this NGS study, we were able to demonstrate the aberrations in genes disturbing different signaling pathways, particularly those relating to the regulation of EMT. Moreover, we were able to demonstrate the crosstalk among the frequently mutated genes TP53, FGFR3, PIK3CA or ATM from a representative list of the altered miRNA transcripts (presented in Fig.
6 and Figure S4), serving as therapeutic intervention points or as potential biomarkers.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.